Program
ammoxetine
Also written as “Ammoxetine hydrochloride enteric-coated tablets”, “Ammoxetine” and “ammoxetine hydrochloride enteric-coated tablets”.
Its studies are mostly in Depressive Disorder, Major · Depression, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 103 open or running | phase 3since Dec 30, 2024 | Aug 9, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2017First study: phase 1 study in DepressionFirst studyNCT03456388 · 58 enrolled · China
- Feb 20, 2019Phase 1 study in DepressionNCT03850834 · 36 enrolled
- Jul 30, 2021Phase 2 study in Depressive Disorder, MajorNCT05018013 · 240 enrolled · China
- Jan 28, 2023Phase 2 study in Depressive Disorder, MajorNCT05762458 · 240 enrolled
- Dec 30, 2024Phase 3 study in Depressive Disorder, MajorNCT06827431 · 786 enrolled · China
- Mar 24, 20262 phase 1 studies in Healthy ParticipantsNCT07508501, NCT07508462
- Jul 2, 20263 phase 1 studies in Healthy ParticipantsNCT07756996, NCT07694869, NCT07694843
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07694869Healthy Participants · China | 1 | Recruiting | Oct 10, 2026 | 16 |
| NCT07694843Healthy Participants · China | 1 | Recruiting | Oct 31, 2026 | 24 |
| NCT07756996Healthy Participants · China | 1 | Recruiting | Aug 31, 2026 | 62 |
| NCT07508501Healthy Participants · China | 1 | Completed | Feb 24, 2023 | 14 |
| NCT07508462Healthy Participants · China | 1 | Completed | Jun 17, 2024 | 18 |
| NCT06827431Depressive Disorder, Major · China | 3 | Completed | Jul 14, 2026 | 786 |
| NCT05762458Depressive Disorder, Major | 2 | UNKNOWN | May 15, 2024 | 240 |
| NCT05018013Depressive Disorder, Major · China | 2 | UNKNOWN | Aug 1, 2022 | 240 |
| NCT03850834Depression | 1 | UNKNOWN | May 31, 2019 | 36 |
| NCT03456388Depression · China | 1 | Completed | Jul 11, 2018 | 58 |
How it is read
Names in the registry
- “Ammoxetine hydrochloride enteric-coated tablets”, 6 entries
- “Ammoxetine”, 3 entries
- “ammoxetine hydrochloride enteric-coated tablets”, 2 entries
- “Ammoxetine Hydrochloride Enteric-coated Tablets”, 2 entries
- “Ammoxetine hydrochloride Enteric-coated Tablets(new formulation)”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 3 studies
- Depression, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.